In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics, with a price target of $90.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors related to Palvella Therapeutics’ recent developments and market potential. The announcement of angiokeratomas as a new indication for their QTORIN 3.9% rapamycin marks an expansion of their clinical programs, which already include microcystic lymphatic malformations and cutaneous venous malformations. This expansion significantly increases the potential patient population in the U.S. to over 150,000 across these indications, highlighting a substantial market opportunity given the lack of FDA-approved treatments for these conditions.
Moreover, the scientific rationale behind using mTOR inhibition to address the pathological mechanisms of angiokeratomas, such as VEGF-driven signaling, supports the potential efficacy of QTORIN 3.9% rapamycin. The planned FDA meeting and subsequent Phase 2 trial initiation in 2026 further demonstrate the company’s commitment to advancing this program. Additionally, Palvella’s financial position, with more than two years of cash runway, provides a stable foundation to pursue these clinical developments, reinforcing the Buy rating.
In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $80.00 price target.